医药中间体市场规模、份额及成长分析（依产品、类别、应用、最终用户及地区划分）－2026-2033年产业预测

预计到 2024 年，医药中间体市场规模将达到 392.3 亿美元，到 2025 年将达到 417.3 亿美元，到 2033 年将达到 683.9 亿美元，在预测期（2026-2033 年）内，复合年增长率为 6.37%。

医药中间体市场在原料药药物成分（API）的生产中扮演着至关重要的角色，尤其是在合成过程中API的形成。这些中间体通常来自煤焦油和石油等优质基础成分，并在製药和化妆品行业中有着广泛的应用。市场成长的驱动力来自对API日益增长的需求，而API需求的成长又受到先进治疗方法和个人化医疗趋势的推动。然而，生物製药的高成本以及API生产所需的大量资本投入等挑战可能会限制其成长潜力。儘管如此，製造技术的进步以及研发投入的增加预计将在不久的将来为医药中间体市场带来巨大的机会，并巩固其市场格局。

医药中间体市场驱动因素

慢性病盛行率的上升以及全球人口老化，显着推动了用于慢性病治疗药物製剂的医药中间体需求的成长。随着包括糖尿病在内的慢性病患者人数的不断增加，医疗保健产业迫切需要开发有效的治疗方法。鑑于慢性病影响相当大比例的人口，显然，对创新药物解决方案的需求庞大。这些趋势正在推动中间体市场的成长，以满足不断增长的需求。

医药中间体市场的限制

生物製药的高昂采购成本对全球医药中间体市场的发展构成重大挑战。此外，活性药物成分（API）生产所需的大量资本投入也阻碍了市场扩张。这些财务壁垒对各相关人员带来障碍，并可能限制其在产业内进行创新和有效竞争的能力。因此，医药中间体市场的整体成长轨迹可能受到不利影响，从而限制新参与企业和现有企业的发展机会。解决这些经济限制因素对于创造更稳健的市场环境至关重要。

医药中间体市场趋势

医药中间体市场的一个显着趋势是慢性心血管疾病盛行率的不断上升，这给全球医疗保健带来了沉重负担。人们对心臟衰竭和缺血性心臟疾病等心臟疾病日益关注，推动了对创新医学中间体的需求，这些中间体有助于开发有效的治疗方法。由于缺血性心臟疾病影响全球数百万人，製药公司正在加大研发投入，以生产能够提高药物疗效和安全性的专用中间体。这种激增的需求为製造商创造了盈利机会，同时也凸显了推动医药技术发展以应对与心血管疾病相关的日益严峻的医疗保健挑战的重要性。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析
• 案例研究分析

全球医药中间体市场规模（依产品及复合年增长率划分）（2026-2033 年）

• 化学中间体
• 医药原料中间体
• 掌性中间体
• 非掌性中间体
• 客製化中间体

全球医药中间体市场规模（依类别划分）及复合年增长率（2026-2033 年）

• 品牌医药中间体
• 学名药中间体

全球医药中间体市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 止痛药
• 抗发炎药
• 循环系统药物
• 抗糖尿病药物
• 抗生素
• 抗癌药物
• 其他的

全球医药中间体市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 生物技术和製药公司
• 研究所
• CMOS／CROS

全球医药中间体市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• BASF SE（Germany）
• Sanofi SA（France）
• Thermo Fisher Scientific Inc.（US）
• Merck KGaA（Germany）
• Dishman Carbogen Amcis Ltd.（India）
• Evonik Industries AG（Germany）
• Arkema Inc.（France）
• Lonza Group AG（Switzerland）
• Wuxi AppTec Co., Ltd.（China）
• Aurobindo Pharma Limited（India）
• Lianhe Chemical Technology Co., Ltd.（China）
• Cambrex Corporation（US）
• Vertellus Holdings LLC（US）
• Hovione LLC（Portugal）
• Hikal Ltd.（India）
• Codexis Inc.（US）
• Aceto Corporation（US）
• Interchem Corporation（US）
• Midas Pharma GmbH（Germany）
• Arbiom（US）

结论与建议

Pharmaceutical Intermediates Market size was valued at USD 39.23 Billion in 2024 and is poised to grow from USD 41.73 Billion in 2025 to USD 68.39 Billion by 2033, growing at a CAGR of 6.37% during the forecast period (2026-2033).

The pharmaceutical intermediates market plays a crucial role as raw materials in the production of bulk drugs, particularly in forming active pharmaceutical ingredients (APIs) during synthesis. These intermediates, often derived from high-quality basic components like coal tar and petroleum, find extensive application in both pharmaceutical and cosmetic sectors. The market is driven by rising demand for APIs, fueled by trends in advanced therapies and personalized medicine. However, challenges such as high costs of biopharmaceutical drugs and significant capital investments for API production may limit growth potential. Nevertheless, advancements in manufacturing technologies and increased investment in research and development are set to unlock substantial opportunities, enhancing the market landscape for pharmaceutical intermediates in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmaceutical Intermediates market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmaceutical Intermediates Market Segments Analysis

Global Pharmaceutical Intermediates Market is segmented by product, category, application, end user and region. Based on product, the market is segmented into chemical intermediates, bulk drug intermediates, chiral intermediates, achiral intermediates and custom intermediates. Based on category, the market is segmented into branded drug intermediates and generic drug intermediates. Based on application, the market is segmented into analgesics, anti-inflammatory drug, cardiovascular drugs, anti-diabetic drugs, antimicrobial drugs, anti-cancer drugs and others. Based on end user, the market is segmented into biotech and pharma companies, research laboratory and CMOS/CROS. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmaceutical Intermediates Market

The rising prevalence of chronic diseases, coupled with a growing elderly population around the globe, significantly contributes to the escalating demand for pharmaceutical intermediates used in drug formulations for chronic disease management. As more individuals are diagnosed with conditions such as diabetes and other chronic ailments, the healthcare sector faces increasing pressure to develop effective treatment options. This trend highlights the urgent need for innovative pharmaceutical solutions, as a substantial portion of the population is affected by chronic illnesses. Consequently, these dynamics are propelling the growth of the pharmaceutical intermediates market to meet this rising demand.

Restraints in the Pharmaceutical Intermediates Market

The significant expenses tied to acquiring biopharmaceutical drugs present a considerable challenge for the advancement of the global pharmaceutical intermediates market. Additionally, the substantial capital investments necessary for the manufacturing of active pharmaceutical ingredients (APIs) further hinder market expansion. These financial barriers create obstacles for various stakeholders, potentially limiting their ability to innovate and compete effectively within the industry. As a result, the overall growth trajectory of the pharmaceutical intermediates market may be adversely affected, restricting opportunities for new entrants and established companies alike. Addressing these economic constraints will be crucial for promoting a more robust market environment.

Market Trends of the Pharmaceutical Intermediates Market

A notable trend in the pharmaceutical intermediates market is the escalating prevalence of chronic cardiovascular diseases, which significantly strains global healthcare systems. Growing concerns over heart conditions like heart failure and ischemic heart disease drive demand for innovative pharmaceutical intermediates that facilitate the development of effective treatments. As ischemic heart disease affects millions worldwide, pharmaceutical companies are increasingly investing in research and development to produce specialized intermediates that enhance drug efficacy and safety. This burgeoning demand presents lucrative opportunities for manufacturers while underscoring the importance of advancements in pharmaceutical technologies to address escalating healthcare challenges associated with cardiovascular diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis
• Case Study Analysis

Global Pharmaceutical Intermediates Market Size by Product & CAGR (2026-2033)

• Market Overview
• Chemical Intermediates
• Bulk Drug Intermediates
• Chiral Intermediates
• Achiral Intermediates
• Custom Intermediates

Global Pharmaceutical Intermediates Market Size by Category & CAGR (2026-2033)

• Market Overview
• Branded Drug Intermediates
• Generic Drug Intermediates

Global Pharmaceutical Intermediates Market Size by Application & CAGR (2026-2033)

• Market Overview
• Analgesics
• Anti-Inflammatory Drug
• Cardiovascular Drugs
• Anti-Diabetic Drugs
• Antimicrobial Drugs
• Anti-Cancer Drugs
• Others

Global Pharmaceutical Intermediates Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biotech And Pharma Companies
• Research Laboratory
• CMOS/CROS

Global Pharmaceutical Intermediates Market Size & CAGR (2026-2033)

• North America (Product, Category, Application, End User)
  • USA
  • Canada
• Europe (Product, Category, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Category, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Category, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Category, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dishman Carbogen Amcis Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evonik Industries AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkema Inc. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi AppTec Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lianhe Chemical Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertellus Holdings LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hovione LLC (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikal Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Codexis Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aceto Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Interchem Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Midas Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbiom (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations